Abstract
e15510 Background: Neoadjuvant therapy with methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) improves survival in LABC. PCG has proven to be an alternative with high response rate in metastatic disease and recent evidences demonstrates it as an option in adjuvant context. However its role in neoadjuvant scenario is still uncertain. Our objective is to evaluate time free of recurrence(TFR) and overall pathologic response in pts with LABC who underwent neoadjuvant PCG. Methods: This is a retrospective cohort study which compares patients(pts) who received neoadjuvant PCG with pts who were submitted to cistectomy alone. TFR was estimated by Kaplan-Meier, log-rank test used to evaluate prognosis factors and Chi square test was used to compares variables. The pathologic specimens were examined by independent pathologists. We considered complete pathologic response (cPR) cases that pathologic staging was T0 or T1 with no nodal involvement. Results: Neoadjuvant therapy with PCG was administered in 16 ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
